Published in J Am Coll Cardiol on May 19, 2004
Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ (2007) 1.81
Achievement of optimal medical therapy goals for U.S. adults with coronary artery disease: results from the REGARDS Study (REasons for Geographic And Racial Differences in Stroke). J Am Coll Cardiol (2014) 1.56
Different treatment options in chronic coronary artery disease: when is it the time for medical treatment, percutaneous coronary intervention or aortocoronary bypass surgery? Dtsch Arztebl Int (2009) 1.18
TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality. PLoS One (2009) 1.11
Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc (2009) 1.00
TCF7L2 variant genotypes and type 2 diabetes risk in Brazil: significant association, but not a significant tool for risk stratification in the general population. BMC Med Genet (2008) 0.93
Higher incidence of death in multi-vessel coronary artery disease patients associated with polymorphisms in chromosome 9p21. BMC Cardiovasc Disord (2012) 0.89
Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. Kidney Int (2016) 0.84
Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. J Cardiothorac Surg (2010) 0.83
The dollars and sense of drug-eluting stents. CMAJ (2005) 0.81
Comparison of percutaneous coronary intervention with drug eluting stents versus coronary artery bypass grafting in patients with multivessel coronary artery disease: Meta-analysis of six randomized controlled trials. Cardiovasc Revasc Med (2015) 0.81
Revascularization treatment in patients with coronary artery disease. Hippokratia (2008) 0.80
Will drug-eluting stents replace coronary artery bypass surgery? Tex Heart Inst J (2005) 0.80
Cardiac complications in type 2 diabetic patients with mild anginal symptoms and documented reversible myocardial perfusion defects: Results of the MERIDIAN trial. Neth Heart J (2006) 0.80
Investigation route of the coronary patient in the public health system in Curitiba, São Paulo and in InCor--IMPACT study. Arq Bras Cardiol (2014) 0.79
Association between UCP2 A55V polymorphism and risk of cardiovascular events in patients with multi-vessel coronary arterial disease. BMC Med Genet (2013) 0.79
Short, Intermediate and long term outcomes of CABG vs. PCI with DES in Patients With Multivessel Coronary Artery Disease. Meta-Analysis of Six Randomized Controlled Trials. Eur J Cardiovasc Med (2014) 0.79
A multi-region assessment of population rates of cardiac catheterization and yield of high-risk coronary artery disease. BMC Health Serv Res (2011) 0.79
Efficacy of Ligustrazine Injection as Adjunctive Therapy for Angina Pectoris: A Systematic Review and Meta-Analysis. Med Sci Monit (2015) 0.78
Changes in practice patterns affecting in-hospital and post-discharge survival among ACS patients. BMC Health Serv Res (2006) 0.78
An Overview on Coronary Heart Disease (A Comparative Evaluation of Turkey and Europe) and Cost-effectiveness of Diagnostic Strategies. Mol Imaging Radionucl Ther (2011) 0.78
The usefulness of xuefu zhuyu tang for patients with angina pectoris: a meta-analysis and systematic review. Evid Based Complement Alternat Med (2014) 0.78
Cardiac risk of coronary patients after reintegration into occupations with heavy physical exertion. Z Kardiol (2005) 0.78
Genetic variants of diabetes risk and incident cardiovascular events in chronic coronary artery disease. PLoS One (2011) 0.77
Surgery, angioplasty, or medical therapy for symptomatic multivessel coronary artery disease: is there an indisputable "winning strategy" from evidence-based clinical trials? J Am Coll Cardiol (2004) 0.76
Appropriateness of diagnosis of unstable angina pectoris in patients referred for coronary arteriography. Exp Clin Cardiol (2008) 0.76
Economic evaluation of increasing population rates of cardiac catheterization. BMC Health Serv Res (2011) 0.75
New Insights in the Diagnosis and Treatment of Heart Failure. Biomed Res Int (2015) 0.75
Coronary artery disease: to cath or not to cath? When and how best to cath: those are the remaining questions. Am J Cardiovasc Dis (2013) 0.75
Medical angioplasty - hope and expectations: an optimistic overview. J Family Community Med (2011) 0.75
Understanding the Outcome of Randomized Trials with Drug-Eluting Stents and Coronary Artery Bypass Graft in Patients with Multivessel Disease: A Review of a 25-Year Journey. Clin Med Insights Cardiol (2016) 0.75
Facts and principles learned at the 39th Annual Williamsburg Conference on Heart Disease. Proc (Bayl Univ Med Cent) (2013) 0.75
Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects. BMC Med Inform Decis Mak (2015) 0.75
Advantage of percutaneous coronary intervention over medical therapy in angina relief and the placebo effect. J Am Coll Cardiol (2005) 0.75
Cardiac outcomes occurred more frequently with PCI than CABG or medical therapy in coronary artery disease. ACP J Club (2004) 0.75
Kidney Function Does Not Modify the Favorable Quality of Life Changes Associated With Revascularization for Coronary Artery Disease: Cohort Study. J Am Heart Assoc (2016) 0.75
Basal hyperinsulinemia beyond a threshold predicts major adverse cardiac events at 1 year after coronary angiogram in type 2 diabetes mellitus: a retrospective cohort study. Diabetol Metab Syndr (2017) 0.75
Non-invasive imaging of a coronary bypass stenosis using CT angiography in a patient with negative stress testing. Int J Cardiovasc Imaging (2005) 0.75
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA (2003) 5.39
Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol (2002) 4.56
ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2012) 4.45
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation (2012) 4.13
Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation (2007) 3.57
Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 3.47
Natural history of asymptomatic mitral valve prolapse in the community. Circulation (2002) 3.40
Controversies in ventricular remodelling. Lancet (2006) 3.39
Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol (2003) 3.20
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol (2003) 3.09
Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation (2003) 2.99
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Controversies in stable coronary artery disease. Lancet (2006) 2.88
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet (2009) 2.82
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol (2008) 2.74
Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab (2005) 2.72
Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med (2003) 2.68
Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation (2010) 2.64
Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol (2006) 2.55
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53
Trends in cause of death after percutaneous coronary intervention. Circulation (2014) 2.52
Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol (2002) 2.50
Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol (2011) 2.49
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation (2007) 2.47
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2008) 2.42
Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol (2007) 2.32
Syncope while driving: clinical characteristics, causes, and prognosis. Circulation (2009) 2.30
Clinical judgment and treatment options in stable multivessel coronary artery disease: results from the one-year follow-up of the MASS II (Medicine, Angioplasty, or Surgery Study II). J Am Coll Cardiol (2006) 2.27
Aborted myocardial infarction: a new target for reperfusion therapy. Eur Heart J (2006) 2.26
Noninvasive estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol (2004) 2.25
Sudden death after myocardial infarction. JAMA (2008) 2.24
Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation (2007) 2.20
The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol (2003) 2.19
Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol (2010) 2.15
Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc (2004) 2.11
Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc (2002) 2.08
Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation (2002) 2.07
Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation (2003) 2.05
Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure. Int J Cardiol (2005) 2.05
Syncope Evaluation in the Emergency Department Study (SEEDS): a multidisciplinary approach to syncope management. Circulation (2004) 2.04
Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol (2003) 2.03
Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J (2008) 2.03
Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol (2002) 2.02
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation (2006) 2.01
Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J (2006) 1.97
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J (2007) 1.92
Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol (2007) 1.91
Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery: a prospective study. J Am Coll Cardiol (2006) 1.88
Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail (2009) 1.87
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol (2004) 1.84
Usefulness of left atrial volume in predicting first congestive heart failure in patients > or = 65 years of age with well-preserved left ventricular systolic function. Am J Cardiol (2005) 1.84
Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 1.83
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82
Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol (2008) 1.78
Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2012) 1.77
Heart failure after myocardial infarction: a review. Am J Med (2002) 1.76
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J (2011) 1.72
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med (2009) 1.72
Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med (2011) 1.70
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2011) 1.70
Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm (2004) 1.70
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol (2009) 1.70
The natural history of lone atrial flutter. Ann Intern Med (2004) 1.68
Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. Mayo Clin Proc (2004) 1.65
Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc (2005) 1.65
Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation (2003) 1.62
Myocardial bridging in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 1.62
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2011) 1.59
Factors associated with longer time from symptom onset to hospital presentation for patients with ST-elevation myocardial infarction. Arch Intern Med (2008) 1.59
Mayo Clinic Risk Score for percutaneous coronary intervention predicts in-hospital mortality in patients undergoing coronary artery bypass graft surgery. Circulation (2008) 1.56
Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J (2007) 1.53
Sudden cardiac death: epidemiology and risk factors. Nat Rev Cardiol (2010) 1.53
How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. Circ Cardiovasc Genet (2009) 1.53
Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol (2005) 1.52
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J (2008) 1.52
Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol (2010) 1.52